STOCK TITAN

Aclarion Inc - ACON STOCK NEWS

Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.

Company Overview

Aclarion Inc (ACON) is a healthcare technology company that leverages the power of Magnetic Resonance Spectroscopy (MRS), proprietary biomarker analysis, and augmented intelligence algorithms to optimize clinical treatments, specifically addressing the pervasive challenge of chronic low back pain. At its core, Aclarion has developed a revolutionary SaaS platform, Nociscan, which noninvasively assists physicians in distinguishing between painful and nonpainful discs. This cutting‐edge solution integrates MRS data collected from standard MRI machines with advanced signal processing techniques to extract and objectively quantify chemical biomarkers associated with disc pain.

Technological Innovation and Clinical Approach

Nociscan stands out in the realm of spine diagnostics by seamlessly combining medical imaging with sophisticated cloud-based algorithms. Once MRS data is transmitted from an MRI, the proprietary system applies unique signal processing methods to capture high-quality biomarker data. This data is then analyzed using augmented intelligence processes to inform clinical decision making, thereby offering a level of diagnostic precision that traditional invasive procedures cannot match.

Operational Model and Revenue Generation

The company’s revenue model is predominantly focused on delivering detailed Nociscan reports to healthcare providers. These reports are generated from contractual arrangements with medical facilities and key specialty centers across the United States. By focusing on a single, high-impact revenue stream, Aclarion is able to dedicate its resources to continuous research and development, solidifying its position as an innovator in noninvasive spine diagnostics.

Clinical Impact and Market Significance

Chronic low back pain remains one of the most common yet challenging conditions to diagnose and manage. Aclarion’s Nociscan provides critical decision support by objectively identifying the chemical biomarkers associated with disc pain, thus aiding physicians in pinpointing the actual source of discomfort. This not only improves the accuracy of treatment plans but also enhances the overall patient care pathway, reducing unnecessary invasive procedures. The strategic use of MRS data in a noninvasive manner marks a significant advance in diagnostic methodology and reinforces the company’s reputation for clinical precision.

Evidence-Based Approach and Industry Recognition

Central to Aclarion’s strategy is the demonstration of strong clinical evidence. The platform is supported by multiple peer-reviewed studies and clinical trials that underscore its efficacy and accuracy. The company’s emphasis on collaborating with key opinion leaders and renowned spine surgeons further solidifies its authority in the healthcare space. Moreover, the continuous evolution of its proprietary technology, combined with strategic partnerships with major imaging providers, positions Aclarion as a pivotal player in the diagnostic imaging and spine care market.

Competitive Landscape and Differentiators

In a market that has traditionally relied on invasive diagnostic procedures such as provocative discography, Aclarion offers a fresh, evidence-supported alternative. Its use of augmented intelligence to enhance the interpretation of MRS data, coupled with a robust patent portfolio and strategic commercial agreements, ensures that it remains at the forefront of innovation. By reducing the need for subjective assessments and invasive methods, Nociscan provides a practical solution that aligns with modern clinical workflows and safety standards.

Clinical Integration and Future Applications

The successful integration of Nociscan into clinical protocols across various imaging centers has demonstrated its practical utility. Physicians have reported that the objective data provided helps refine treatment strategies, ensuring that only the discs contributing to pain are targeted. This has significant implications for both surgical and non-surgical treatment decisions, leading to enhanced outcomes and potentially lower overall healthcare costs. While the system is currently deployed within the chronic low back pain market, its underlying technology suggests potential applications in broader diagnostic contexts, underscoring the transformative potential of leveraging MRS and biomarker data.

Conclusion

Aclarion Inc epitomizes innovation in healthcare technology by harnessing advanced MRS, proprietary signal processing, and AI-enhanced algorithms to address a major clinical challenge. Its SaaS platform, Nociscan, is designed to offer objective, reproducible insights that empower physicians to deliver targeted, effective treatments for chronic low back pain. With a focus on evidence-based clinical outcomes and strategic partnerships that amplify its market presence, Aclarion continues to set a high standard in diagnostic precision and patient care within the healthcare industry.

Rhea-AI Summary
Aclarion, Inc. (ACON) has initiated the CLARITY trial to validate superior surgical outcomes using Nociscan technology. The recent financing transactions have significantly reduced debt and increased available cash, enabling the company to achieve key milestones. The strategic partnership with Alphatec is expected to onboard 5 additional Key Opinion Leader surgeons and increase Nociscan orders. The CLARITY trial will enroll up to 300 patients across 8 sites, with principal investigator Nicholas Theodore, MD, leading the study. Aclarion also aims to add 5 new KOL surgeons to the Nociscan network in the first half of 2024 through the strategic partnership with Alphatec.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
partnership
-
Rhea-AI Summary
Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the product release of Nociscan 2.6, expanding accessibility on the worldwide MRI market. This new release includes support for additional leading MRI scanners beyond those manufactured by Siemens, a major milestone towards making Nociscan available on the leading MRI machines of all manufacturers. The company aims to improve the lives of millions of patients suffering from degenerative spine disease and low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) partners with Alphatec Spine, Inc. (Nasdaq: ATEC) to integrate Aclarion’s Nociscan technology, the first augmented intelligence platform to measure pain biomarkers in the lumbar spine, into ATEC’s AlphaInformatiX platform. The partnership aims to improve clinical outcomes and reduce procedural costs for patients with chronic low back pain, leveraging ATEC’s surgeon network and providing ATEC with exclusive distribution rights for Nociscan. Aclarion’s published trials confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes, with a peer-reviewed publication demonstrating an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, compared to 63% for inconsistent treatment strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
partnership
-
News
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a 1-for-16 reverse stock split effective before market open on January 4, 2024, to meet Nasdaq listing standards. The split will increase the per share price and bid price of its common stock above the $1.00 required by Nasdaq’s Minimum Bid Price Rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
-
Rhea-AI Summary
Aclarion, Inc. (ACON) has completed 1,000 commercial Nociscan exams, with the pace of commercial adoption accelerating. The company's CEO, Brent Ness, highlighted the achievement and the strategy that led to it. Aclarion's Chief Strategy Officer, Ryan Bond, emphasized the importance of Nociscan in transforming complex data into individualized biomarker reports for chronic low back pain patients. The company holds a disruptive innovation with a strong patent portfolio and aims to address the high healthcare spending on low back and neck pain in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Aclarion (ACON) successfully enrolls 10 leading spine surgery KOLs to drive Nociscan to standard of care for identifying discogenic low back pain. The company will activate MRIs for each KOL surgeon to expand Nociscan access and demonstrate clinical outcome improvements to payers, with initial scan volume data to be released by the end of the year. The recruitment of renowned KOL surgeons is a critical step in establishing Nociscan as the standard of care for diagnosing and treating low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, has announced that Dr. Roger Hartl, a renowned neurosurgeon, will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain noninvasively. Dr. Hartl will have access to an MRI center authorized to perform Nociscans in New York City, adding to the existing site in Denver. Aclarion plans to report on Nociscan volumes before the end of the year and include this metric in quarterly reporting from 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, announced that its Nociscan platform will be presented at the NIH HEAL Initiative BACPAC Research Program. Nociscan is a decision support tool that helps physicians identify the location of chronic low back pain. It is being utilized in two leading low back pain trials within the HEAL Initiative. The NIH HEAL Initiative aims to address the opioid crisis by funding research on chronic low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
none
Rhea-AI Summary
Porter Hospital in Denver has become the first facility to offer Nociscan technology for chronic low back pain patients. The technology measures biomarkers to pinpoint the source of pain and has been shown to improve patient outcomes and reduce costs. Aclarion, the healthcare technology company behind Nociscan, is expanding its footprint in Colorado with AdventHealth Porter. The addition of Nociscan to the hospital's diagnostic evaluation is expected to improve treatment strategies and provide personalized biomarker data to physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
none

FAQ

What is the current stock price of Aclarion (ACON)?

The current stock price of Aclarion (ACON) is $10.82 as of April 4, 2025.

What is the market cap of Aclarion (ACON)?

The market cap of Aclarion (ACON) is approximately 5.8M.

What is the primary focus of Aclarion Inc?

Aclarion Inc is focused on advancing healthcare technology by leveraging Magnetic Resonance Spectroscopy (MRS), biomarkers, and augmented intelligence to diagnose chronic low back pain noninvasively through its SaaS platform, Nociscan.

How does the Nociscan platform work?

Nociscan receives MRS data from MRI machines and employs proprietary signal processing techniques to extract and quantify chemical biomarkers linked to disc pain, providing physicians with objective, data-driven insights.

What is the company’s revenue model?

The company generates revenue primarily by delivering detailed Nociscan reports to healthcare providers under contractual arrangements, predominantly across the United States.

What differentiates Aclarion’s technology in the diagnostic imaging sector?

Aclarion’s technology stands out because it combines noninvasive MRS data with AI-driven algorithms to provide clear, objective assessments of disc pain, reducing reliance on invasive diagnostic procedures.

Who typically uses Aclarion’s Nociscan system?

The primary users include physicians, spine surgeons, and diagnostic imaging centers, along with key opinion leaders in the field of spine care who rely on objective data for treatment planning.

How does Aclarion ensure the accuracy of its diagnostic tool?

Accuracy is ensured through advanced proprietary signal processing methods and extensive clinical validation via peer-reviewed studies and multi-center clinical trials that substantiate its efficacy.

How does Aclarion's approach impact patient care?

By providing a noninvasive, evidence-based tool for identifying painful discs, Nociscan aids physicians in making precise treatment decisions, which can lead to improved clinical outcomes and a reduction in unnecessary invasive procedures.

What role do clinical trials and research play at Aclarion?

Clinical trials and research are central to Aclarion's strategy as they validate the clinical utility of Nociscan, support its evidence-based approach, and help secure broader acceptance among healthcare providers and payers.
Aclarion Inc

Nasdaq:ACON

ACON Rankings

ACON Stock Data

5.84M
507.41k
46.39%
Health Information Services
Services-medical Laboratories
Link
United States
BROOMFIELD